Published in TB and Outbreaks Week, July 29th, 2003
The agreement gives OneWorld Health the exclusive license to develop the azole compounds to treat parasitic diseases in the developing world. OneWorld Health will initially focus on the use of the azoles in Chagas disease, the leading cause of heart failure in Latin America, where 16-18 million people are infected and another 100 million are at risk.
The disease is most often...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.